Prospective Evaluation of Single‐Time‐Point Methotrexate Monitoring During High‐Dose Therapy in Pediatric Leukemias and Lymphomas
Rattachement africain : in. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Conventional multi-time point monitoring during high-dose methotrexate (HD-MTX) therapy is often impractical in low- and middle-income countries (LMICs). A simplified single-time-point monitoring strategy may offer a feasible alternative. OBJECTIVES: To determine the proportion of patients achieving adequate MTX clearance (≤0.4 µmol/L) at 48 h following initiation of HD-MTX. METHODOLOGY: In this prospective observational study, children with high-risk B-lineage and T-cell acute lymphoblastic leukemia receiving HD-MTX were enrolled. Single time point MTX levels were measured 48 h from initiation of infusion. MTX level >0.4 µmol/L received intensified hydration and leucovorin rescue. Toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Patients with pre-existing renal insufficiency or prior Grades 3 and 4 MTX toxicity were excluded. RESULTS: Thirty-two children (age 2-12 years) undergoing 106 cycles of HD-MTX were evaluated. MTX clearance at 48 h was achieved in 74.5% (79/106). Delayed clearance normalized at 72 h in 5/16 retested cycles. Age >7 years (p = 0.025) and higher baseline serum creatinine (p = 0.022) predicted delayed clearance. Elevated 48-h levels correlated with neutropenia (13%, p = 0.0096), transaminitis, mucositis, and acute kidney injury occurred in 10.4%, 7.5%, and 3.8% of cycles. CONCLUSIONS: A single 48-h MTX level can facilitate discharge decisions in approximately 75% of treatment cycles in a preselected cohort of patients. This approach may provide a pragmatic and cost-effective strategy in resource-limited settings, though its safety in unselected populations remains to be established. Validation in larger, unselected cohorts is needed before broad implementation can be recommended.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prospective Evaluation of Single‐Time‐Point Methotrexate Monitoring During High‐Dose Therapy in Pediatric Leukemias and Lymphomas
- Date Crossref
- 10/09/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.